{
  "id": "52b2e409f828ad283c00000e",
  "type": "factoid",
  "question": "What disease in Loxapine prominently used for?",
  "ideal_answer": "The best indication of loxapine is paranoid schizophrenia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22014696",
    "http://www.ncbi.nlm.nih.gov/pubmed/7914051"
  ],
  "snippets": [
    {
      "text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014696",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine, loxapine, zuclopenthixol, and flupentixol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014696",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Loxapine has been prescribed in France since 1980. Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7914051",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008152",
    "http://www.biosemantics.org/jochem#4090321",
    "http://www.biosemantics.org/jochem#4274767",
    "http://www.biosemantics.org/jochem#4122154"
  ],
  "exact_answer": "schizophrenia"
}